"I'd say a year before we get a prototype vetted by an interested party and then a year more for them to test it in their labs.
Two years minimum". I agree, and not just for a medical device. I don't see any major revenue over the next two year+. What then happens to the company? More dilution, that is certainly the track record. Predictably, reverse splits on top of that.
For longs, it is not a hill too far, the dilution is a mountain too high. We would be lucky to see a buyout at $1, but I don't know who would pay that much for the IP. Do the math folks, with this many shares, throw in the towel on a $10 stock at your current share count.